Venture Life (VLG) AI Stock Analysis

• Market Cap: £79.80M
• Dividend Yield: N/A
• Average Volume (3M): 139.02K
• Price to Earnings (P/E): 2.8
• Beta (1Y): 0.32
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: UK
• Employees: 165
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.03
• Shares Outstanding: 121,828,070
• 10 Day Avg. Volume: 191,491
• 30 Day Avg. Volume: 139,016
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.04
• Price to Sales (P/S): 2.40
• P/FCF Ratio: -273.16
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 0.04
• Revenue Forecast (FY): £35.10M

• Rating: 60 Neutral
• Price Target: 68.00 p ▲(3.82% Upside)
• Action: Reiterated Date: 04/09/26
• Date: Action: Reiterated 04/09/26

The score is primarily supported by improved profitability and a substantially de-risked balance sheet (very low debt). Offsetting this are the 2025 swing to negative operating/free cash flow and volatile revenue/margins, while technicals remain weak despite oversold readings; valuation is also difficult to support with a negative P/E and no dividend yield provided.

Positive Factors

De-risked Balance Sheet

The sharp debt reduction to roughly £0.7m materially de-risks the capital structure, giving management flexibility to fund product development, support contract-manufacturing obligations, or weather demand swings without urgent refinancing. Low leverage improves strategic optionality over the next several quarters.

Negative Factors

Negative Cash Flow in 2025

The reversal to negative operating and free cash flow in 2025 breaks a prior multi-year pattern of solid cash conversion and suggests working-capital strain or one-off items. If cash generation remains weak, the company may need external funding or to draw reserves, constraining reinvestment and increasing execution risk over the medium term.

Venture Life Business Overview & Revenue Model

Company Description

Venture Life Group plc develops and commercializes oral care products, food supplements, medical devices, dermo-cosmetics, and topical products for the ageing population in the United Kingdom, the Netherlands, China, Germany, Italy, Switzerland, r...

Read more

Venture Life Group plc develops and commercializes oral care products, food supplements, medical devices, dermo-cosmetics, and topical products for the ageing population in the United Kingdom, the Netherlands, China, Germany, Italy, Switzerland, r...

How the Company Makes Money

Venture Life makes money primarily through (1) sales of its own branded consumer healthcare products and (2) revenue from contract development and manufacturing activities for other companies. 1) Branded product sales (core revenue stream): The c...

Read more

Venture Life makes money primarily through (1) sales of its own branded consumer healthcare products and (2) revenue from contract development and manufacturing activities for other companies. 1) Branded product sales (core revenue stream): The c...

Venture Life Financial Statement Overview

Breakdown	Dec 2025	Jun 2025	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	35.17M	26.59M	51.41M	43.98M	32.76M
Gross Profit	11.79M	12.19M	20.15M	17.66M	12.96M
EBITDA	5.08M	4.32M	9.95M	7.61M	5.16M
Net Income	6.13M	-314.00K	921.00K	520.00K	2.40M
Balance Sheet
Total Assets	99.18M	124.49M	119.50M	125.29M	103.63M
Cash, Cash Equivalents and Short-Term Investments	34.17M	3.05M	5.62M	5.63M	5.24M
Total Debt	667.00K	23.86M	24.39M	26.85M	12.73M
Total Liabilities	17.76M	49.08M	43.24M	49.63M	30.47M
Stockholders Equity	81.42M	75.41M	76.25M	75.66M	73.16M
Cash Flow
Free Cash Flow	-309.00K	8.34M	5.81M	1.36M	-2.66M
Operating Cash Flow	-264.00K	8.35M	8.22M	5.57M	601.00K
Investing Cash Flow	53.98M	-11.29M	-5.34M	-11.69M	-39.18M
Financing Cash Flow	-23.77M	1.78M	-2.81M	6.92M	1.50M

Venture Life Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 65.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:VLG, the sentiment is Negative. The current price of 65.5 is below the 20-day moving average (MA) of 67.19, below the 50-day MA of 68.25, and above the 200-day MA of 61.59, indicating a neutral trend. The MACD of -1.09 indicates Positive momentum. The RSI at 32.17 is Neutral, neither overbought nor oversold. The STOCH value of 22.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:VLG.

Venture Life Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HLN	67 Neutral	£32.48B	20.15	6.43%	1.51%	-2.12%	42.10%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
VLG	60 Neutral	£79.80M	2.80	7.82%	―	―	―
STX	47 Neutral	£100.86M	-4.82	206.44%	―	93.48%	51.18%
AGY	45 Neutral	£683.91M	-7.21	409.00%	―	-0.28%	22.94%
PXS	45 Neutral	£22.29M	-11.67	-51.21%	―	61.13%	33.33%

Venture Life Corporate Events